文献速递造血干细胞移植与细胞治疗

G20国家商业CAR-T细胞疗法的卫生技术评估与可及性横断面研究

Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries.
PubMed 文献 · Blood · 2026-01-01

该横断面研究分析了G20成员国及3个受邀国截至2025年8月1日对18个FDA批准的CAR-T产品-适应症组合的HTA评估。常见障碍包括单臂试验设计、样本量小及生存、安全性和生活质量数据不成熟。

要点

  • FDA批准至HTA决策中位时间1.54年,延迟明显。
  • 单臂试验、小样本和数据不成熟是HTA评估的主要障碍。

核心结论

  • 即使在高收入和中高收入国家,CAR-T疗法可及性仍存在显著全球差异,亟需科学和政策手段降低成本并改善可及性。

研究设计与样本

  • 横断面分析,纳入G20成员国及3个受邀国(西班牙、新加坡、瑞士),分析截至2025年8月1日的HTA评估文档。

主要发现

  • FDA批准至HTA决策的中位时间为1.54年(四分位距1.15-2.59)。
  • HTA报告常引用的成本效果障碍包括单臂试验设计、研究人群小以及生存、安全性和生活质量数据不成熟。

关键数值与推荐

  • 18个CAR-T产品-适应症组合对应当前FDA批准。

临床怎么用

  • 血液科医生应了解CAR-T疗法在不同国家的报销状态和HTA决策延迟,为患者提供可及性预期。
  • HTA障碍提示需积累更成熟生存、安全性和生活质量数据以支持报销决策。

局限性

  • 分析截至2025年8月1日,后续HTA决策未纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cells are a major treatment advance for many patients with hematological malignancies, especially those with disease that has relapsed or is refractory to chemotherapy. However, currently approved commercial autologous CAR T cells require highly specialized manufacturing processes that contribute to high costs and limit their widespread use. In many countries, positive reimbursement recommendations by health technology assessment (HTA) bodies enable patient access to CAR T therapies. We performed a cross-sectional analysis of HTA evaluations of commercial CAR T therapies among the Group of 20 (G20) member countries plus 3 G20 invitees (Spain, Singapore, and Switzerland) through 1 August 2025. Across the 18 CAR T product-indication pairs with current US Food and Drug Administration (FDA) approval, we analyzed HTA review documentation to ascertain the timing and rationale for a positive or negative recommendation. Fourteen countries with public HTA data were included in our analysis. Forty-eight percent of CAR T-indication pairs (122/252) are currently recommended for reimbursement by public health systems. The median time from FDA approval to HTA decision was 1.54 years (interquartile range, 1.15-2.59). Common barriers to CAR T cost-effectiveness cited in HTA reports included single-arm trial designs, small study populations, and immature data regarding survival, safety, and quality of life. Our findings demonstrate substantial global disparities in access to CAR T treatments even among high-income and upper middle-income countries, highlighting the urgent need for both scientific and policy approaches to reduce costs and improve access to these impactful therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ge AY, Feldman WB, Kaiser MF, et al. Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries. Blood. 2026. PMID: 41543441. doi:10.1182/blood.2025030872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。